# BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

> **NCT00949650** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 345 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** BIBW 2992
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00949650
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-14
- **Primary completion:** 2012-02-09
- **Final completion:** 2017-03-16
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00949650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00949650, "BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00949650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*